Search Results

he DESTINY-Breast06 (DB-06) trial explored the effectiveness of trastuzumab deruxtecan (T-DXd) in patients with hormone receptor-positive (HR+), HER2-low or HER2-ultralow metastatic breast cancer (mBC). Patients were screened for HER2 status and randomized to receive either T-DXd or treatment of the physician's choice (TPC). Results showed that T-DXd significantly improved progression-free survival (PFS) compared to TPC, across various HER2 classifications.

Providing valuable insights into the findings from key studies including DESTINY-Breast06 (NCT04494425), postMONARCH (NCT05169567), and TBCRC 048 (olaparib expanded) (NCT02032823), Dr. Tolaney explores the potential impact these results could have on clinical practice.

Welcome to the latest issue of touchREVIEWS in Oncology & Haematology. We are honoured to present a series of compelling articles that reflect cutting-edge developments and diverse perspectives in this ever-evolving field. This issue includes a series of editorials and reviews from esteemed experts who provide insights into novel therapies and their potential to change […]

Trastuzumab deruxtecan (T-DXd) is a novel human epidermal growth factor receptor 2 (HER2)-targeted antibody–drug conjugate (ADC) designed to effectively deliver a potent topoisomerase I inhibitor (exatecan derivative) to HER2-expressing cancer cells and limit potential systemic toxicity.1 T-DXd has shown remarkable efficacy against recurrent HER2-positive breast cancer in many trials.2–5 This payload, an exatecan derivative, is highly active among camptothecins […]

Gastric and gastro-oesophageal junction (GOJ) adenocarcinomas are highly aggressive tumours with an overall poor prognosis, which is primarily attributable to the late stage of diagnosis resulting from nonspecific symptoms.1,2 While curative surgical resection is recommended for early-stage cases,3 advanced disease is treated with palliative intent, employing chemotherapy, immunotherapy and targeted therapies.4 The backbone of first-line treatment in […]

Data released from the KEYNOTE-585 (NCT03221426), KEYNOTE-811 (NCT03615326), MATTERHORN (NCT04592913) and SANO (NCT05491616) trials, were some of the most anticipated results and highlights in upper gastrointestinal cancer presented at EMSO 2023. To summarise the findings from these key studies and their impact on the treatment of upper gastrointestinal cancers we caught up with esophageal oncologist […]

Significant advancements in breast cancer research emerged from ESMO 2023. To highlight these key data we spoke with prominent breast medical oncologist, Dr. Sara Tolaney (Dana-Farber Cancer Institute, Boston). In this interview, Dr. Tolaney highlights some of the most valuable data including those from the KEYNOTE-756 (NCT03725059), Checkmate-7FL (NCT04109066), TOPION-Breast01 (NCT05104866) and monarchE (NCT03155997) breast […]

The final results of the phase 3, TULIP trial (NCT03262935), which compared trastuzumab duocarmazine (T-Duo) with physician’s choice of therapy in previously treated HER2-positive metastatic breast cancer, were presented at ESMO 2023.  Dr. Philippe Aftimos, the study investigator from the Institute Jules Bordet in Belgium, presented the results at the conference and then discussed them […]